ArticleJournal of transplantation2014
Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma.
Article in Journal of transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation.Current oncology (Toronto, Ont.) · 2026Review
- A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction.Hepatology (Baltimore, Md.) · 2025Article
- Prognostic nomogram for recurrence of hepatocellular carcinoma after liver transplantation for decision making on postoperative adjuvant therapy.Scientific reports · 2025Article
- Sorafenib as Adjuvant Therapy Post-Liver Transplant: A Single-center Experience.Transplantation direct · 2025Article
- Review
- Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.Cancer immunology, immunotherapy : CII · 2024Article
- Recent Advances in Liver Transplantation for Hepatocellular Carcinoma.Current treatment options in oncology · 2024Review
- Growing need of adjuvant therapy and expanded access for liver transplant in hepatocellular carcinoma.Annals of translational medicine · 2023Article
- Advances in postoperative adjuvant therapy for primary liver cancer.World journal of gastrointestinal oncology · 2022Review
- Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.Liver cancer · 2022Review
- Review
- Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study.Frontiers in oncology · 2020Article
- Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy.OncoTargets and therapy · 2019Article
- Sorafenib in adjuvant setting: call for precise and personalized therapy.Translational gastroenterology and hepatology · 2016Article
- Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.Translational gastroenterology and hepatology · 2016Review
- Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.World journal of gastroenterology · 2015Review
- Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.World journal of hepatology · 2015Review
- The effect of sorafenib on liver regeneration and angiogenesis after partial hepatectomy in rats.HippokratiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of liver transplantation (LT) for hepatocellular (HCC) is limited by tumor recurrence rates of 10-15%. We undertook this pilot study to examine the use of sorafenib as adjuvant therapy in high-risk LT recipients. Methods. We prospectively enrolled patients transplanted for HCC into a treatment protocol utilizing sorafenib if their explant examination showed evidence of viable tumor exceeding Milan criteria. We utilized as historical controls patients transplanted previously, whose explant tumor characteristics exceeded Milan criteria, but who were not "preemptively" treated with sorafenib. Wilcoxon two-sample test and Fisher's exact test were used to compare survival and recurrence rates between the two groups. Results. Seven patients were treated with sorafenib and compared to 12 historical "controls." Two of 7 treated patients suffered from HCC recurrence. Of the comparison group, 9 experienced HCC recurrence and all succumbed to disease. Dose reduction improved tolerance of drug. The overall rate of HCC recurrence was decreased in the adjuvant therapy group compared to historical controls (29% versus 75%, P = 0.07). Disease free 1-year survival for the treated versus untreated group was 100% versus 66%, respectively. Conclusion. Adjuvant use of sorafenib is safe and decreases risk of HCC recurrence in high-risk LT recipients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.